These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 311684)
1. Dose-dependent adjuvant effects of Bacillus Calmette-Guérin on tumor immunity in Lewis rats. Davies M; Sabbadini E Cancer Res; 1979 Mar; 39(3):959-65. PubMed ID: 311684 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine. Hanna MG; Peters LC Cancer Res; 1978 Jan; 38(1):204-9. PubMed ID: 201374 [TBL] [Abstract][Full Text] [Related]
3. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin. Braun DP; Mokyr MB; Dray S Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676 [TBL] [Abstract][Full Text] [Related]
4. Preoperative intralesional Bacillus Calmette-Guérin for mammary adenocarcinoma in rats. Lee YT Cancer Res; 1977 Oct; 37(10):3679-83. PubMed ID: 908015 [TBL] [Abstract][Full Text] [Related]
5. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma. Kreider JW; Bartlett GL; Boyer CM; Purnell DM Cancer Res; 1979 Mar; 39(3):987-92. PubMed ID: 427785 [TBL] [Abstract][Full Text] [Related]
6. Influence of preexisting tumor immunity on Bacillus Calmette-Guérin immunotherapy of guinea pigs with both regional and disseminated tumor. Jessup JM; Riggs CW; Hanna MG Cancer Res; 1977 Aug; 37(8 Pt 1):2565-73. PubMed ID: 872084 [No Abstract] [Full Text] [Related]
7. Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Albright L; Madigan JC; Gaston MR; Houchens DP Cancer Res; 1975 Mar; 35(3):658-65. PubMed ID: 234790 [TBL] [Abstract][Full Text] [Related]
8. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R; Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161 [TBL] [Abstract][Full Text] [Related]
10. Cross-reactivity between Bacillus Calmette-Guérin and Rous Virus-induced sarcoma detected in rats by tube leukocyte adherence inhibition assay. Holán V; Chutná J; Hasek M Cancer Res; 1979 Feb; 39(2 Pt 2):593-6. PubMed ID: 216490 [TBL] [Abstract][Full Text] [Related]
11. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes]. Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436 [TBL] [Abstract][Full Text] [Related]
12. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin. Dubois JB; Serrou B Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530 [TBL] [Abstract][Full Text] [Related]
13. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study. Pan CW; Shen ZJ; Ding GQ J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576 [TBL] [Abstract][Full Text] [Related]
14. Endogenous production of cytotoxic factors in serum of BCG-primed mice by monophosphoryl lipid A, a detoxified form of endotoxin. Bennett JA; Peters JH; Chudacoff R; McKneally MF J Biol Response Mod; 1988 Feb; 7(1):65-76. PubMed ID: 3373236 [TBL] [Abstract][Full Text] [Related]
15. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010 [TBL] [Abstract][Full Text] [Related]
16. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy. Vaage J Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431 [TBL] [Abstract][Full Text] [Related]